oncnursingnews2 天
FDA Accepts New Drug Application to Darolutamide Plus ADP for mHSPC
The FDA accepted a supplemental new drug application to darolutamide plus androgen deprivation therapy for metastatic hormone ...
oncnursingnews3 天
Rapid Taper Plays Role in Suspected Opioid Misuse in Patients With Cancer
Clinicians should consider a rapid taper approach for patients with cancer who exhibit repeated signs of opioid misuse, an ...
oncnursingnews3 天
FDA Fast Tracks ALE.P02 for CLDN1-Poisitive Solid Cancers
The FDA granted a fast track designation to ALE-P02 for patients with CLDN1-positive squamous solid tumors. The FDA granted ...
oncnursingnews3 天
Bernardo L. Rapoport, MD
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
oncnursingnews3 天
Donna L. Berry, PhD, RN, AOCN, FAAN
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
oncnursingnews4 天
Eric Blackstone, MA, Sara L. Douglas, PhD, RN, Amy R. Lipson, PhD
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
oncnursingnews5 天
Subcutaneous Pembrolizumab Is Noninferior to IV Formulation in NSCLC
Subcutaneous pembrolizumab plus chemotherapy was noninferior to IV pembrolizumab plus chemotherapy in treatment-naïve non-small cell lung cancer. Pembrolizumab (Keytruda) and berahyaluronidase alfa ...
oncnursingnews5 天
Patricia Kropf, MD
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
oncnursingnews6 天
Mirdametinib Boosts Outcomes, QOL in NF1-PN
Mirdametinib led to confirmed responses and meaningful pain and health-related quality of life improvements in both children and adults with neurofibromatosis type 1-associated PNs.